Boston Scientific To Acquire Silk Road Medical For $1.16B In Cash, Offering $44 Per Share; 30% Premium Over Last Closing Price; Deal To Enhance Neurovascular Portfolio And Close By Q4 2024 Pending Regulatory Approvals
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific is set to acquire Silk Road Medical for $1.16 billion in cash, offering $44 per share, which is a 30% premium over the last closing price. The deal aims to enhance Boston Scientific's neurovascular portfolio and is expected to close by Q4 2024, pending regulatory approvals.
June 20, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Boston Scientific's acquisition of Silk Road Medical for $1.16 billion in cash at a 30% premium is expected to enhance its neurovascular portfolio. The deal is anticipated to close by Q4 2024, pending regulatory approvals.
The acquisition is a strategic move to enhance Boston Scientific's neurovascular portfolio, which is likely to be viewed positively by investors. The 30% premium indicates strong confidence in Silk Road Medical's value.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Silk Road Medical is being acquired by Boston Scientific for $1.16 billion in cash at $44 per share, a 30% premium over the last closing price. The deal is expected to close by Q4 2024, pending regulatory approvals.
The acquisition at a 30% premium is likely to result in a short-term increase in Silk Road Medical's stock price as investors react to the favorable terms of the deal.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100